Last reviewed · How we verify
Oracure gel
Oracure gel is a Small molecule drug developed by Hams Hamed Abdelrahman. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Oracure gel |
|---|---|
| Sponsor | Hams Hamed Abdelrahman |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Low Level Laser Therapy and Lidocaine Versus Chlorhexidine for the Management of Traumatic Oral Ulcers in Children (NA)
- N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients (NA)
- Adjunctive Treatments for the Prevention of Radiotherapy-Induced Mucositis (NA)
- Probiotic Lozenges for Treatment of Recurrent Aphthous Stomatitis (NA)
- Topical Chamomile in Preventing Chemotherapy-induced Oral Mucositis (PHASE2)
- Vitamin D Oral Gel for Prevention of Radiation Induced Oral Mucositis (PHASE2)
- Melatonin for Prevention of Radiation Induced Oral Mucositis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oracure gel CI brief — competitive landscape report
- Oracure gel updates RSS · CI watch RSS
- Hams Hamed Abdelrahman portfolio CI
Frequently asked questions about Oracure gel
What is Oracure gel?
Who makes Oracure gel?
What development phase is Oracure gel in?
Related
- Manufacturer: Hams Hamed Abdelrahman — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing